Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Market Insights on Castration-Resistant Prostate Cancer (CRPC) Treatment covering sales outlook, demand forecast & up-to-date key trends
Castration-Resistant Prostate Cancer (CRPC) Treatment Market by Therapy Type, Drug Class, Drug Delivery Method, Distribution Channel & Region | Forecast 2023 to 2033
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Snapshot
The global castration-resistant prostate cancer (CRPC) treatment market is expected to garner a market value of US$ 11.3 Billion in 2023 and is expected to accumulate a market value of US$ 28 Billion by registering a CAGR of 9.5% in the forecast period 2023 to 2033. Growth of the castration-resistant prostate cancer (CRPC) treatment market can be attributed to increasing prevalence of the ailment and use of combination therapies to treat the ailment. The market for castration-resistant prostate cancer (CRPC) treatment registered a CAGR of 6% in the historical period 2018 to 2022
Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer that has become resistant to traditional hormone therapy (also known as androgen deprivation therapy or ADT). In CRPC, the cancer continues to grow despite low levels of testosterone in the body, which is typically the result of surgical or medical castration.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 11.3 Billion |
|
Anticipated Forecast Value (2033) |
US$ 28 Billion |
|
Projected Growth Rate (2023 to 2033) |
9.5% CAGR |
Let us know your requirement to get
100% FREE customization
2018 to 2022 Castration-Resistant Prostate Cancer (CRPC) Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Castration-Resistant Prostate Cancer (CRPC) Treatment reflected a value of 6% during the historical period, 2018 to 2022.
Increasing prevalence of prostate cancer, the development of new therapies, and the rising demand for personalized medicine is driving the growth of the castration-resistant prostate cancer (CRPC) treatment market. Moreover, research and development along with technological integration for innovating medication is expected to bolster the demand for treatment of castration-resistant prostate cancer (CRPC) treatment market.
Thus, the market for Castration-Resistant Prostate Cancer (CRPC) Treatment is expected to register a CAGR of 9.5% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Castration-Resistant Prostate Cancer (CRPC) Treatment Market?
Availability of diagnostic tools shaping landscape for CRPC market
The increasing incidence of prostate cancer, which is one of the most common cancers among men, is driving the demand for effective treatments for CRPC. The development of new treatment options, including targeted therapies, immunotherapies, and radiopharmaceuticals, has expanded the range of options available for the treatment of CRPC.
The aging population is more susceptible to prostate cancer and CRPC, and this demographic trend is increasing the demand for effective treatments for this disease. The availability of diagnostic tools such as imaging technologies, genomic testing, and liquid biopsies has improved the detection and monitoring of CRPC, which is contributing to the demand for effective treatments.
The increasing research and development activities in the field of oncology, including prostate cancer, are leading to the development of new and innovative treatments for CRPC. The government initiatives aimed at increasing awareness of prostate cancer and improving access to healthcare services are contributing to the growth of the CRPC treatment market.
Presence of different treatments creative lucrative opportunities for CRPC market
Second-line hormone therapy: This involves the use of different types of hormone therapy drugs that target different aspects of the androgen receptor pathway.
Chemotherapy: Chemotherapy drugs such as docetaxel and cabazitaxel may be used to treat CRPC.
Immunotherapy: Immune checkpoint inhibitors such as pembrolizumab and nivolumab have been approved for the treatment of certain types of CRPC.
Radiopharmaceutical therapy: Radiopharmaceuticals such as radium-223 and lutetium-177 PSMA have been approved for the treatment of CRPC that has spread to the bones.
Targeted therapy: Targeted drugs such as enzalutamide, abiraterone, and apalutamide may be used to treat CRPC by blocking specific pathways that fuel the growth of cancer cells.
Clinical trials: Participation in clinical trials of new treatments is also an option for some patients with CRPC.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?
Limited efficiency of treatments along with expensive nature of treatment affecting market growth
Many of the available treatment options for CRPC are expensive, and this can make them inaccessible to patients who cannot afford them or are not covered by health insurance. The side effects of many CRPC treatments, such as chemotherapy and immunotherapy, can be severe and impact a patient's quality of life. This can make it challenging for patients to tolerate the treatments and continue with their treatment plans.
While there are several treatment options available for CRPC, not all of them are effective for every patient. Some patients may not respond to certain treatments, and this can limit the efficacy of the available options. Some patients may develop resistance to the available treatments, which can make it challenging to manage their disease and prolong their survival.
Despite the advances in research and development, the underlying mechanisms of CRPC are not fully understood, and this can make it challenging to develop new and more effective treatments. Developing new treatments for CRPC can be challenging due to regulatory requirements, including the need for extensive clinical trials to demonstrate safety and efficacy. All these factors are derailing the growth of CRPC market.
Region-Wise Insights
Advanced Healthcare Infrastructure Boosting Market Growth of CRPC in North America?
Newer targeted therapies creating lucrative opportunities for CPRC treatment
The North American market for Castration-Resistant Prostate Cancer (CRPC) treatment is one of the largest markets in the world, due to the high prevalence of prostate cancer in the region and the availability of advanced healthcare infrastructure.
In terms of treatment options, chemotherapy and hormone therapy have been the mainstays of CRPC treatment in North America for many years, but newer targeted therapies such as abiraterone, enzalutamide, apalutamide, and radium-223 have also been approved for use. Immunotherapy, such as the use of immune checkpoint inhibitors, is also being investigated for CRPC treatment. Thus, North America is expected to possess 46% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
Introduction of Novel Treatments Supporting Growth of CRPC Treatment Market in Europe?
Increasing awareness of diagnosis propelling demand for CRPC treatment in Europe
The Europe CRPC treatment market is being driven by the increasing prevalence of the disease in the region, as well as the growing awareness and diagnosis of the disease. In addition, the market is being driven by the introduction of novel treatments that offer better efficacy and fewer side effects than traditional therapies.
One of the most promising developments in CRPC treatment is the use of targeted therapies. These drugs are designed to specifically target the cancer cells and limit their growth and spread, while minimizing damage to healthy cells. Targeted therapies such as enzalutamide and abiraterone have shown significant benefits in treating CRPC, leading to their approval by regulatory agencies in Europe. Thus, Europe is expected to possess 40% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
Ease and Accessibility of Consuming Oral Medications Making Them Popular for CRPC Treatment?
Ease to administer oral medication increasing dependency to treat CRPC treatment
The oral route offers patients the convenience of taking medication in the comfort of their own homes. This is particularly beneficial for CRPC patients, who may need to take medication for extended periods of time. Oral medications can be taken without the need for hospital visits or invasive procedures, making treatment more accessible and less disruptive to a patient's daily life.
In addition, the oral route of administration can help to improve patient adherence to treatment. Patients are more likely to take their medication as prescribed when it is delivered in a convenient, easy-to-administer format. This is particularly important in the treatment of CRPC, where adherence to therapy is crucial for achieving positive treatment outcomes. Thus, by drug delivery method, oral route is expected to possess 55% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
Market Competition
Key players in the castration-resistant prostate cancer (CRPC) treatment market are Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc, Dendreon Corporation
- In 2018, Sanofi and Regeneron Pharmaceuticals announced the results of a phase 3 clinical trial investigating the use of their immunotherapy drug, cemiplimab, in combination with Jevtana for the treatment of metastatic CRPC. The trial showed promising results, with the combination therapy significantly improving overall survival and progression-free survival compared to Jevtana alone.
- In 2019, Pfizer announced the results of a phase 3 clinical trial investigating the use of Xtandi in combination with abiraterone acetate, another androgen receptor inhibitor, for the treatment of metastatic CRPC.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 11.3 Billion |
|
Market Value in 2033 |
US$ 28 Billion |
|
Growth Rate |
CAGR of 9.5% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Castration-Resistant Prostate Cancer (CRPC) Treatment Industry Survey
Therapy Type:
- Hormonal therapy
- Chemotherapy
- Immunotherapy
- Radiotherapy
Drug Class:
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Microtubule Inhibitor
Drug Delivery Method:
- Oral Route
- Injectable Route
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
Frequently Asked Questions
At what rate did the Castration-Resistant Prostate Cancer (CRPC) Treatment market flourish from 2018-2022?
From 2018 to 2022, the Castration-Resistant Prostate Cancer (CRPC) Treatment market grew at a CAGR of 6%
What will be the growth rate of the global Castration-Resistant Prostate Cancer (CRPC) Treatment market during the forecast period?
The global Castration-Resistant Prostate Cancer (CRPC) Treatment market is expected to grow with a 9.5% CAGR during 2023 to 2033.
What will be the projected market size of the Castration-Resistant Prostate Cancer (CRPC) Treatment market by 2033?
As of 2033, the Castration-Resistant Prostate Cancer (CRPC) Treatment market is expected to reach US$ 28 Billion
Which drug delivery segment is expected to dominate the global Castration-Resistant Prostate Cancer (CRPC) Treatment market during 2033?
Oral route are expected to hold 55% of the market share in 2023 for Castration-Resistant Prostate Cancer (CRPC) Treatment market.
How is the North America Castration-Resistant Prostate Cancer (CRPC) Treatment market projected to grow in 2033?
North America is expected to possess 46% market share for Castration-Resistant Prostate Cancer (CRPC) Treatment market in 2023.
How is the Europe Castration-Resistant Prostate Cancer (CRPC) Treatment market projected to grow in 2033?
Europe Castration-Resistant Prostate Cancer (CRPC) Treatment market size is expected to possess 40% market share in 2023.
Table of Content
1. Executive Summary | Castration-Resistant Prostate Cancer (CRPC) Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033 5.3.1. Hormonal therapy 5.3.2. Chemotherapy 5.3.3. Immunotherapy 5.3.4. Radiotherapy 5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 6.3.1. Antineoplastic 6.3.2. Non-steroidal Antiandrogen 6.3.3. Corticosteroids 6.3.4. Microtubule Inhibitor 6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Delivery Method 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Drug Delivery Method , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Delivery Method , 2023 to 2033 7.3.1. Oral Route 7.3.2. Injectable Route 7.4. Y-o-Y Growth Trend Analysis By Drug Delivery Method , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Drug Delivery Method , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Online Pharmacies 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. MEA 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Therapy Type 10.2.3. By Drug Class 10.2.4. By Drug Delivery Method 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Therapy Type 10.3.3. By Drug Class 10.3.4. By Drug Delivery Method 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Therapy Type 11.2.3. By Drug Class 11.2.4. By Drug Delivery Method 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Therapy Type 11.3.3. By Drug Class 11.3.4. By Drug Delivery Method 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United Kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Therapy Type 12.2.3. By Drug Class 12.2.4. By Drug Delivery Method 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Therapy Type 12.3.3. By Drug Class 12.3.4. By Drug Delivery Method 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Therapy Type 13.2.3. By Drug Class 13.2.4. By Drug Delivery Method 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Therapy Type 13.3.3. By Drug Class 13.3.4. By Drug Delivery Method 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Therapy Type 14.2.3. By Drug Class 14.2.4. By Drug Delivery Method 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Therapy Type 14.3.3. By Drug Class 14.3.4. By Drug Delivery Method 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Therapy Type 15.2.3. By Drug Class 15.2.4. By Drug Delivery Method 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Therapy Type 15.3.3. By Drug Class 15.3.4. By Drug Delivery Method 15.3.5. By Distribution Channel 15.4. Key Takeaways 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Therapy Type 16.2.3. By Drug Class 16.2.4. By Drug Delivery Method 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Therapy Type 16.3.3. By Drug Class 16.3.4. By Drug Delivery Method 16.3.5. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Therapy Type 17.1.2.2. By Drug Class 17.1.2.3. By Drug Delivery Method 17.1.2.4. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Therapy Type 17.2.2.2. By Drug Class 17.2.2.3. By Drug Delivery Method 17.2.2.4. By Distribution Channel 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Therapy Type 17.3.2.2. By Drug Class 17.3.2.3. By Drug Delivery Method 17.3.2.4. By Distribution Channel 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Therapy Type 17.4.2.2. By Drug Class 17.4.2.3. By Drug Delivery Method 17.4.2.4. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Therapy Type 17.5.2.2. By Drug Class 17.5.2.3. By Drug Delivery Method 17.5.2.4. By Distribution Channel 17.6. United Kingdom 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Therapy Type 17.6.2.2. By Drug Class 17.6.2.3. By Drug Delivery Method 17.6.2.4. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Therapy Type 17.7.2.2. By Drug Class 17.7.2.3. By Drug Delivery Method 17.7.2.4. By Distribution Channel 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Therapy Type 17.8.2.2. By Drug Class 17.8.2.3. By Drug Delivery Method 17.8.2.4. By Distribution Channel 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Therapy Type 17.9.2.2. By Drug Class 17.9.2.3. By Drug Delivery Method 17.9.2.4. By Distribution Channel 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Therapy Type 17.10.2.2. By Drug Class 17.10.2.3. By Drug Delivery Method 17.10.2.4. By Distribution Channel 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Therapy Type 17.11.2.2. By Drug Class 17.11.2.3. By Drug Delivery Method 17.11.2.4. By Distribution Channel 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Therapy Type 17.12.2.2. By Drug Class 17.12.2.3. By Drug Delivery Method 17.12.2.4. By Distribution Channel 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Therapy Type 17.13.2.2. By Drug Class 17.13.2.3. By Drug Delivery Method 17.13.2.4. By Distribution Channel 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Therapy Type 17.14.2.2. By Drug Class 17.14.2.3. By Drug Delivery Method 17.14.2.4. By Distribution Channel 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Therapy Type 17.15.2.2. By Drug Class 17.15.2.3. By Drug Delivery Method 17.15.2.4. By Distribution Channel 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Therapy Type 17.16.2.2. By Drug Class 17.16.2.3. By Drug Delivery Method 17.16.2.4. By Distribution Channel 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Therapy Type 17.17.2.2. By Drug Class 17.17.2.3. By Drug Delivery Method 17.17.2.4. By Distribution Channel 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Therapy Type 17.18.2.2. By Drug Class 17.18.2.3. By Drug Delivery Method 17.18.2.4. By Distribution Channel 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Therapy Type 17.19.2.2. By Drug Class 17.19.2.3. By Drug Delivery Method 17.19.2.4. By Distribution Channel 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Therapy Type 17.20.2.2. By Drug Class 17.20.2.3. By Drug Delivery Method 17.20.2.4. By Distribution Channel 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Therapy Type 17.21.2.2. By Drug Class 17.21.2.3. By Drug Delivery Method 17.21.2.4. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Therapy Type 18.3.3. By Drug Class 18.3.4. By Drug Delivery Method 18.3.5. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Sanofi S.A. 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Johnson and Johnson 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Pfizer, Inc. 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Bayer AG 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Abbott Laboratories 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. GlaxoSmithKline PLC 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Northwest Biotherapeutics, Inc. 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Active Biotech AB 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Astellas Pharma, Inc. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Dendreon Corporation 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Drug Delivery Method , 2018 to 2033 Table 5: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 9: North America Market Value (US$ Million) Forecast by Drug Delivery Method , 2018 to 2033 Table 10: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033 Table 13: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 14: Latin America Market Value (US$ Million) Forecast by Drug Delivery Method , 2018 to 2033 Table 15: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: Europe Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033 Table 18: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 19: Europe Market Value (US$ Million) Forecast by Drug Delivery Method , 2018 to 2033 Table 20: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 21: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: South Asia Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033 Table 23: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 24: South Asia Market Value (US$ Million) Forecast by Drug Delivery Method , 2018 to 2033 Table 25: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 26: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 27: East Asia Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033 Table 28: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 29: East Asia Market Value (US$ Million) Forecast by Drug Delivery Method , 2018 to 2033 Table 30: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 31: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 32: Oceania Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033 Table 33: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 34: Oceania Market Value (US$ Million) Forecast by Drug Delivery Method , 2018 to 2033 Table 35: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 36: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 37: MEA Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033 Table 38: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 39: MEA Market Value (US$ Million) Forecast by Drug Delivery Method , 2018 to 2033 Table 40: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Therapy Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Drug Delivery Method , 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 9: Global Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033 Figure 10: Global Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033 Figure 11: Global Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033 Figure 12: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 13: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 14: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 15: Global Market Value (US$ Million) Analysis by Drug Delivery Method , 2018 to 2033 Figure 16: Global Market Value Share (%) and BPS Analysis by Drug Delivery Method , 2023 to 2033 Figure 17: Global Market Y-o-Y Growth (%) Projections by Drug Delivery Method , 2023 to 2033 Figure 18: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 21: Global Market Attractiveness by Therapy Type, 2023 to 2033 Figure 22: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 23: Global Market Attractiveness by Drug Delivery Method , 2023 to 2033 Figure 24: Global Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 25: Global Market Attractiveness by Region, 2023 to 2033 Figure 26: North America Market Value (US$ Million) by Therapy Type, 2023 to 2033 Figure 27: North America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 28: North America Market Value (US$ Million) by Drug Delivery Method , 2023 to 2033 Figure 29: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033 Figure 37: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 38: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 39: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 40: North America Market Value (US$ Million) Analysis by Drug Delivery Method , 2018 to 2033 Figure 41: North America Market Value Share (%) and BPS Analysis by Drug Delivery Method , 2023 to 2033 Figure 42: North America Market Y-o-Y Growth (%) Projections by Drug Delivery Method , 2023 to 2033 Figure 43: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 46: North America Market Attractiveness by Therapy Type, 2023 to 2033 Figure 47: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 48: North America Market Attractiveness by Drug Delivery Method , 2023 to 2033 Figure 49: North America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 50: North America Market Attractiveness by Country, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) by Therapy Type, 2023 to 2033 Figure 52: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 53: Latin America Market Value (US$ Million) by Drug Delivery Method , 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 59: Latin America Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033 Figure 60: Latin America Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033 Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033 Figure 62: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 63: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 65: Latin America Market Value (US$ Million) Analysis by Drug Delivery Method , 2018 to 2033 Figure 66: Latin America Market Value Share (%) and BPS Analysis by Drug Delivery Method , 2023 to 2033 Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Drug Delivery Method , 2023 to 2033 Figure 68: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 71: Latin America Market Attractiveness by Therapy Type, 2023 to 2033 Figure 72: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 73: Latin America Market Attractiveness by Drug Delivery Method , 2023 to 2033 Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 76: Europe Market Value (US$ Million) by Therapy Type, 2023 to 2033 Figure 77: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 78: Europe Market Value (US$ Million) by Drug Delivery Method , 2023 to 2033 Figure 79: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 80: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 84: Europe Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033 Figure 85: Europe Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033 Figure 86: Europe Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033 Figure 87: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 88: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 89: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 90: Europe Market Value (US$ Million) Analysis by Drug Delivery Method , 2018 to 2033 Figure 91: Europe Market Value Share (%) and BPS Analysis by Drug Delivery Method , 2023 to 2033 Figure 92: Europe Market Y-o-Y Growth (%) Projections by Drug Delivery Method , 2023 to 2033 Figure 93: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 96: Europe Market Attractiveness by Therapy Type, 2023 to 2033 Figure 97: Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 98: Europe Market Attractiveness by Drug Delivery Method , 2023 to 2033 Figure 99: Europe Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 100: Europe Market Attractiveness by Country, 2023 to 2033 Figure 101: South Asia Market Value (US$ Million) by Therapy Type, 2023 to 2033 Figure 102: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 103: South Asia Market Value (US$ Million) by Drug Delivery Method , 2023 to 2033 Figure 104: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 105: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 106: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 109: South Asia Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033 Figure 110: South Asia Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033 Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033 Figure 112: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 113: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 115: South Asia Market Value (US$ Million) Analysis by Drug Delivery Method , 2018 to 2033 Figure 116: South Asia Market Value Share (%) and BPS Analysis by Drug Delivery Method , 2023 to 2033 Figure 117: South Asia Market Y-o-Y Growth (%) Projections by Drug Delivery Method , 2023 to 2033 Figure 118: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 119: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 120: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 121: South Asia Market Attractiveness by Therapy Type, 2023 to 2033 Figure 122: South Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 123: South Asia Market Attractiveness by Drug Delivery Method , 2023 to 2033 Figure 124: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 125: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 126: East Asia Market Value (US$ Million) by Therapy Type, 2023 to 2033 Figure 127: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 128: East Asia Market Value (US$ Million) by Drug Delivery Method , 2023 to 2033 Figure 129: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 130: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 131: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 134: East Asia Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033 Figure 135: East Asia Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033 Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033 Figure 137: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 138: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 140: East Asia Market Value (US$ Million) Analysis by Drug Delivery Method , 2018 to 2033 Figure 141: East Asia Market Value Share (%) and BPS Analysis by Drug Delivery Method , 2023 to 2033 Figure 142: East Asia Market Y-o-Y Growth (%) Projections by Drug Delivery Method , 2023 to 2033 Figure 143: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 144: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 145: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 146: East Asia Market Attractiveness by Therapy Type, 2023 to 2033 Figure 147: East Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 148: East Asia Market Attractiveness by Drug Delivery Method , 2023 to 2033 Figure 149: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 150: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 151: Oceania Market Value (US$ Million) by Therapy Type, 2023 to 2033 Figure 152: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 153: Oceania Market Value (US$ Million) by Drug Delivery Method , 2023 to 2033 Figure 154: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 155: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 156: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 159: Oceania Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033 Figure 160: Oceania Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033 Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033 Figure 162: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 163: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 165: Oceania Market Value (US$ Million) Analysis by Drug Delivery Method , 2018 to 2033 Figure 166: Oceania Market Value Share (%) and BPS Analysis by Drug Delivery Method , 2023 to 2033 Figure 167: Oceania Market Y-o-Y Growth (%) Projections by Drug Delivery Method , 2023 to 2033 Figure 168: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 169: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 170: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 171: Oceania Market Attractiveness by Therapy Type, 2023 to 2033 Figure 172: Oceania Market Attractiveness by Drug Class, 2023 to 2033 Figure 173: Oceania Market Attractiveness by Drug Delivery Method , 2023 to 2033 Figure 174: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 175: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 176: MEA Market Value (US$ Million) by Therapy Type, 2023 to 2033 Figure 177: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 178: MEA Market Value (US$ Million) by Drug Delivery Method , 2023 to 2033 Figure 179: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 180: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 181: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 184: MEA Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033 Figure 185: MEA Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033 Figure 186: MEA Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033 Figure 187: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 188: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 189: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 190: MEA Market Value (US$ Million) Analysis by Drug Delivery Method , 2018 to 2033 Figure 191: MEA Market Value Share (%) and BPS Analysis by Drug Delivery Method , 2023 to 2033 Figure 192: MEA Market Y-o-Y Growth (%) Projections by Drug Delivery Method , 2023 to 2033 Figure 193: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 194: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 195: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 196: MEA Market Attractiveness by Therapy Type, 2023 to 2033 Figure 197: MEA Market Attractiveness by Drug Class, 2023 to 2033 Figure 198: MEA Market Attractiveness by Drug Delivery Method , 2023 to 2033 Figure 199: MEA Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 200: MEA Market Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
